CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Mitoxantrone

米托蒽醌 杂质对照品Mitoxantrone Impurities

EP25 个杂质条目25 impurity entries

本页汇总 米托蒽醌 的 25 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 25 impurity reference standards of Mitoxantrone with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 米托蒽醌(Mitoxantrone)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesIsolation and identification of a new impurity in mitoxantrone hydrochloride
    Die Pharmazie · 2009 · Haiyan L  ·  PMID 19618673
  2. 杂质研究Impurity studiesInvestigating the interaction of mitoxantrone with anionic surfactants by spectrofluorimetry and its application for the feasible analysis of pharmaceutical preparation and biological fluids
    Luminescence : the journal of biological and chemical luminescence · 2021 · Hamad AA et al.  ·  PMID 33047899  ·  DOI
  3. 杂质研究Impurity studiesThe genotoxicity of the anti-cancer drug mitoxantrone in somatic and germ cells of Drosophila melanogaster
    Mutation research · 1992 · Frei H et al.  ·  PMID 1374529  ·  DOI
  4. 分析方法Analytical MethodsHPLC analysis of mitoxantrone in mouse plasma and tissues: application in a pharmacokinetic study
    Journal of pharmaceutical and biomedical analysis · 2010 · An G, Morris ME  ·  PMID 19850431  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisStudies towards the synthesis of dicarboxylic acid metabolite of mitoxantrone: PS177
    Porto biomedical journal · 2017 · Hrynchak I et al.  ·  PMID 32258719  ·  DOI

米托蒽醌 —— 原料药与杂质对照品Mitoxantrone — drug substance & impurities

共 26 个条目(含原料药本体)26 items incl. the drug substance
Mitoxantrone structure
EP原料药 APIAPI
米托蒽醌Mitoxantrone
Mitoxantrone
CAS No.65271-80-9
Chemical FormulaC22H28N4O6
Purity>95%询价On request
10mg25mg50mg100mg
Mitoxantrone Impurity 1 Monomer(Mitoxantrone EP Impurity A Monomer) structure
EPA
米托蒽醌杂质1单体(米托蒽醌EP杂质A单体)Mitoxantrone Impurity 1 Monomer(Mitoxantrone EP Impurity A Monomer)
Mitoxantrone Impurity 1 Monomer(Mitoxantrone EP Impurity A Monomer)
CAS No.89991-52-6
Chemical FormulaC18H19N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Mitoxantrone Impurity 1 Hydrochloride(Mitoxantrone EP Impurity A Hydrochloride) structure
EPA
米托蒽醌杂质1盐酸盐(米托蒽醌EP杂质A盐酸盐)Mitoxantrone Impurity 1 Hydrochloride(Mitoxantrone EP Impurity A Hydrochloride)
Mitoxantrone Impurity 1 Hydrochloride(Mitoxantrone EP Impurity A Hydrochloride)
CAS No.89991-54-8
Chemical FormulaC18H19N3O5·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Mitoxantrone Impurity 2(Mitoxantrone EP Impurity B) structure
EPB
米托蒽醌杂质2(米托蒽醌EP杂质B)Mitoxantrone Impurity 2(Mitoxantrone EP Impurity B)
Mitoxantrone Impurity 2(Mitoxantrone EP Impurity B)
CAS No.80189-44-2
Chemical FormulaC22H28N4O5
Purity>95%询价On request
10mg25mg50mg100mg
Mitoxantrone Impurity 3(Mitoxantrone EP Impurity C) structure
EPC
米托蒽醌杂质3(米托蒽醌EP杂质C)Mitoxantrone Impurity 3(Mitoxantrone EP Impurity C)
Mitoxantrone Impurity 3(Mitoxantrone EP Impurity C)
CAS No.1796928-50-1
Chemical FormulaC22H27ClN4O6
Purity>95%询价On request
10mg25mg50mg100mg
Mitoxantrone Impurity 4 Monomer(Mitoxantrone EP Impurity D Monomer) structure
EPD
米托蒽醌杂质4单体(米托蒽醌EP杂质D单体)Mitoxantrone Impurity 4 Monomer(Mitoxantrone EP Impurity D Monomer)
Mitoxantrone Impurity 4 Monomer(Mitoxantrone EP Impurity D Monomer)
CAS No.137132-70-8
Chemical FormulaC22H26N4O6
Purity>95%询价On request
10mg25mg50mg100mg
Mitoxantrone Impurity 4(Mitoxantrone EP Impurity D) structure
EPD
米托蒽醌杂质4(米托蒽醌EP杂质D)Mitoxantrone Impurity 4(Mitoxantrone EP Impurity D)
Mitoxantrone Impurity 4(Mitoxantrone EP Impurity D)
CAS No.261164-09-4
Chemical FormulaC22H27ClN4O6
Purity>95%询价On request
10mg25mg50mg100mg
Mitoxantrone Impurity N1 structure
N1
米托蒽醌杂质N1Mitoxantrone Impurity N1
Mitoxantrone Impurity N1
CAS No.81-59-4
Chemical FormulaC14H10O6
Purity>95%现货In stock
10mg25mg50mg100mg
Mitoxantrone Impurity 8 structure
8
米托蒽醌杂质8Mitoxantrone Impurity 8
Mitoxantrone Impurity 8
CAS No.476-43-7
Chemical FormulaC15H10O6
Purity>95%询价On request
10mg25mg50mg100mg
Mitoxantrone Impurity 9 structure
9
米托蒽醌杂质9Mitoxantrone Impurity 9
Mitoxantrone Impurity 9
CAS No.1519-36-4
Chemical FormulaC16H12O2
Purity>95%询价On request
10mg25mg50mg100mg
Mitoxantrone Impurity 12 structure
12
米托蒽醌杂质12Mitoxantrone Impurity 12
Mitoxantrone Impurity 12
CAS No.145-49-3
Chemical FormulaC14H10N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Mitoxantrone Impurity 13 structure
13
米托蒽醌杂质13Mitoxantrone Impurity 13
Mitoxantrone Impurity 13
CAS No.70476-74-3
Chemical FormulaC22H30N4O6
Purity>95%询价On request
10mg25mg50mg100mg
Mitoxantrone Impurity 14 structure
14
米托蒽醌杂质14Mitoxantrone Impurity 14
Mitoxantrone Impurity 14
CAS No.81-60-7
Chemical FormulaC14H8O6
Purity>95%询价On request
10mg25mg50mg100mg
Mitoxantrone Impurity 15 structure
15
米托蒽醌杂质15Mitoxantrone Impurity 15
Mitoxantrone Impurity 15
CAS No.6374-78-3
Chemical FormulaC14H9NO5
Purity>95%询价On request
10mg25mg50mg100mg
Mitoxantrone Impurity 17 structure
17
米托蒽醌杂质17Mitoxantrone Impurity 17
Mitoxantrone Impurity 17
CAS No.70476-65-2
Chemical FormulaC26H32N4O6
Purity>95%询价On request
10mg25mg50mg100mg
Mitoxantrone Impurity 18 structure
18
米托蒽醌杂质18Mitoxantrone Impurity 18
Mitoxantrone Impurity 18
CAS No.80173-32-6
Chemical FormulaC22H29N5O4
Purity>95%询价On request
10mg25mg50mg100mg
Mitoxantrone Impurity 19 structure
19
米托蒽醌杂质19Mitoxantrone Impurity 19
Mitoxantrone Impurity 19
CAS No.144510-98-5
Chemical FormulaC17H17N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Mitoxantrone Impurity 20 structure
20
米托蒽醌杂质20Mitoxantrone Impurity 20
Mitoxantrone Impurity 20
CAS No.96555-65-6
Chemical FormulaC18H20N4O4
Purity>95%询价On request
10mg25mg50mg100mg
Mitoxantrone Impurity 21 structure
21
米托蒽醌杂质21Mitoxantrone Impurity 21
Mitoxantrone Impurity 21
CAS No.134566-65-7
Chemical FormulaC22H28N4O5
Purity>95%询价On request
10mg25mg50mg100mg
Mitoxantrone Impurity 22 structure
22
米托蒽醌杂质22Mitoxantrone Impurity 22
Mitoxantrone Impurity 22
CAS No.70476-71-0
Chemical FormulaC24H34N4O4
Purity>95%询价On request
10mg25mg50mg100mg
Mitoxantrone Impurity 23 (N1-Nitroso Mitoxantrone) structure
23
米托蒽醌杂质23 (N1-亚硝基米托蒽醌)Mitoxantrone Impurity 23 (N1-Nitroso Mitoxantrone)
Mitoxantrone Impurity 23 (N1-Nitroso Mitoxantrone)
CAS No.3080808-23-4
Chemical FormulaC22H27N5O7
Purity>95%询价On request
10mg25mg50mg100mg
Mitoxantrone Impurity 25 structure
25
米托蒽醌杂质25Mitoxantrone Impurity 25
Mitoxantrone Impurity 25
CAS No.69837-14-5
Chemical FormulaC14H10O6
Purity>95%询价On request
10mg25mg50mg100mg
Mitoxantrone Impurity 26 structure
26
米托蒽醌杂质26Mitoxantrone Impurity 26
Mitoxantrone Impurity 26
CAS No.478-35-3
Chemical FormulaC16H12O6
Purity>95%询价On request
10mg25mg50mg100mg
Mitoxantrone Impurity 29 structure
29
米托蒽醌杂质29Mitoxantrone Impurity 29
Mitoxantrone Impurity 29
CAS No.128-94-9
Chemical FormulaC14H10N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Mitoxantrone Impurity 30 structure
30
米托蒽醌杂质30Mitoxantrone Impurity 30
Mitoxantrone Impurity 30
CAS No.77184-75-9
Chemical FormulaC18H18N2O6
Purity>95%询价On request
10mg25mg50mg100mg
Mitoxantrone Impurity 42 structure
42
米托蒽醌杂质42Mitoxantrone Impurity 42
Mitoxantrone Impurity 42
CAS No.100495-30-5
Chemical FormulaC20H22N2O4
Purity>95%询价On request
10mg25mg50mg100mg
本品种含亚硝胺类杂质条目。亚硝胺杂质属于 ICH M7 关注的潜在致突变杂质,建议在方法开发中纳入专属性考察。This list includes nitrosamine entries. Nitrosamines are potential mutagenic impurities under ICH M7 and should be covered by a specific method.

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

米托蒽醌 —— 研究文献与合成路线Mitoxantrone — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 米托蒽醌 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Mitoxantrone. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Targeting the ERα DBD-LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
    Wang H, Luo Y, Artham S, et al. · Molecular cancer therapeutics · 2026
  2. Isolation and identification of a new impurity in mitoxantrone hydrochloride
    Haiyan L · Die Pharmazie · 2009
  3. Identification of mitoxantrone as a potent inhibitor of CDK7/Cyclin H via structure-based virtual screening and In-Vitro validation by ADP-Glo kinase assay
    Somarowthu T, Patekar RR, Bharate SB · Bioorganic chemistry · 2025 · 被引 6cited 6
  4. Polarographic determination of mitoxantrone in pharmaceutical preparations and biological media
    Golabi SM, Hassan-Zadeh V · Talanta · 1996 · 被引 10cited 10
  5. A novel HPLC method for the determination of mitoxantrone in pharmaceutical formulations
    Ficarra R, Ficarra P, Calabrò ML, et al. · Bollettino chimico farmaceutico · 1992 · 被引 1cited 1

合成与制备工艺专利Synthesis & process patents

  1. Mitoxantrone or liposome of mitoxantrone hydrochloric acid, and preparation method
    ZHANG GUOXI WENG · 公开号 CN1915220CN1915220 · 2007
  2. USE OF GLATIRAMER ACETATE AND MITOXANTRONE IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
    VOLLMER TIMOTHY · 公开号 IL171956IL171956 · 2011

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

米托蒽醌 杂质谱研究要点Mitoxantrone — impurity profiling notes

下面这些是拿到 米托蒽醌 的 26 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 26 impurity entries for Mitoxantrone, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances